Dolphin Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 28-12-2024
- Paid Up Capital ₹ 3.00 M
as on 28-12-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 18.10%
(FY 2022)
- Profit 16.67%
(FY 2022)
- Ebitda -327.07%
(FY 2022)
- Net Worth 9.84%
(FY 2022)
- Total Assets -45.13%
(FY 2022)
About Dolphin Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Jaysukhbhai Zalawadiya, Dilipbhai Zalawadiya, and Hareshkumar Sorathiya serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PLC064980
- Company No.
064980
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Apr 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dolphin Pharmaceutical Limited offer?
Dolphin Pharmaceutical Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Catheter, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Surgical & ICU Equipments, Ventilator Parts & Consumables, Face Mask & Medical PPE Kits, Disposable Gloves, Anti Infective Drugs & Medicines, HIV Drugs.
Who are the key members and board of directors at Dolphin Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaysukhbhai Zalawadiya  | Director | 16-Apr-2011 | Current |
| Dilipbhai Zalawadiya | Director | 16-Apr-2011 | Current |
| Hareshkumar Sorathiya | Director | 16-Apr-2011 | Current |
Financial Performance of Dolphin Pharmaceutical.
Dolphin Pharmaceutical Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 18.1% increase. The company also saw a substantial improvement in profitability, with a 16.67% increase in profit. The company's net worth moved up by a moderate rise of 9.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dolphin Pharmaceutical?
In 2022, Dolphin Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Janvi Impex Private LimitedActive 16 years 10 monthsJaysukhbhai Zalawadiya and Hareshkumar Sorathiya are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dolphin Pharmaceutical?
Unlock and access historical data on people associated with Dolphin Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dolphin Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dolphin Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
